Red Sox lefty Chris Sale has avoided the worst case scenario — for now. That’s the good news. But the situation “sucks,” he acknowledged in a discussion with reporters including Ian Browne of MLB.com (links to Twitter).

Sale has not incurred new damage to the ulnar collateral ligament in his pitching elbow. But he’s still not in the clear. His most recent attempt to ramp up ran into yet more elbow trouble, casting doubt as to whether he can proceed without surgical intervention.

At this point, the veteran southpaw says, he simply doesn’t know what to anticipate. On the one hand, there’s still hope that he’ll be able to return relatively early in the 2020 season. Once the inflammation subsides in a few weeks’ time, he’ll attempt to start throwing again. If everything goes well, Sale might conceivably miss only a month or so of action.

And what if the elbow keeps barking? That would seem to put an end to the rest-and-rehab approach that he and the team have employed since last summer. Sale acknowledged that Tommy John surgery is a possibility. It isn’t entirely clear whether other surgical approaches may also be considered.

It’s a tough spot for the Red Sox, who have $145MM invested in the star southpaw for the next five seasons. Sale offered a tough self-assessment. “I was able to get through most of my career doing what I love to do and helping my team win,” he said. “For sure, over the last year and up to this point, I’ve done nothing but fall flat on my face.”

Those harsh words are surely a reflection of a trying situation. But it’s hard to fault Sale himself for the fix he’s in. He has long been durable, productive, and (by all indications) hard-working. Unfortunately, elbow woes are common for hurlers.

March 5: Sale has been diagnosed with a flexor strain, Roenicke tells reporters (Twitter link via Mastrodonato). He’ll be shut down from throwing until next week and even then will be limited to simply playing catch. The next steps will depend on how he responds to that activity. Roenicke notes that Sale’s “UCL looks the same as the last image.”

March 4, 4:35pm: At this point, there’s no expectation that Sale will require Tommy John surgery, Ken Rosenthal of The Athletic tweets.

9:05am: We learned yesterday that star Red Sox lefty Chris Sale had undergone an MRI after he experienced elbow soreness, with Dr. James Andrews set to review the results. That has now occurred, but a diagnosis and course of treatment remain unknown.

Boston manager Ron Roenicke tells reporters, including Jason Mastrodonato of the Boston Herald (Twitter link) and Peter Abraham of the Boston Globe (Twitter link), that the club has sought another opinion. Another premier specialist, Dr. Neal ElAttrache, will review the imaging and weigh in with his opinion.

Presumably, the hope is to land upon a consensus after receiving the viewpoints of Andrews, ElAttrache, and the Sox’ own team medical staff. All involved are taking their time, says Roenicke, because there’s a “need to get this right.”

Sale will ultimately decide upon what course of treatment he deems best. But there’s a shared interest in arriving upon the best long-term approach to his as-yet-unclear elbow ailment. The Red Sox owe Sale $145MM over the next five seasons.

Roenicke says that fans and media shouldn’t read into the ongoing uncertainty. Sale isn’t necessarily staring down Tommy John surgery, it seems. Indeed, it’s not really even clear whether that is a possibility on the table at the moment.

What is known to this point: Sale was shut down and received platelet-rich plasma treatment in August after visiting Andrews. The southpaw said he had been cleared of ligament damage. He was cleared to throw over the winter; indications were that he’d be a full participant in Spring Training. Sale was delayed at the outset of camp, with the explanation given that he was dealing with a case of pneumonia, but began throwing recently without evident issue. But his elbow began barking after facing live hitters recently, prompting this new round of medical analysis.